Cooley advised Dynavax Technologies, a publicly traded vaccines company with a marketed adult hepatitis B vaccine (HEPLISAV-B), a shingles vaccine candidate and a differentiated clinical-stage pipeline, on its definitive agreement to be acquired by Sanofi for $15.50 per share in cash, representing an equity value of $2.2 billion. The acquisition strengthens Sanofi’s position in adult immunization by bringing together Dynavax’s adult hepatitis B vaccine and promising shingles asset with Sanofi’s global scale, development capabilities and commercial reach.